Takeda
-
With global innovation map further expanded, Ascentage Pharma saw a 477% surge in revenue in the first half of 2024
The development of original new drugs has always been considered a high-risk industry. A d…
-
Morphic’s stock prices soar by 75%! Eli Lilly invests an additional $3.2 billion in the autoimmune field
DrugTimes will present more reports timely. Please stay tuned
-
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Congratulations! This is the latest cross-border licensing out deal by a pharma/biotech in China
-
TOP PHARMAS BY 2024 PIPELINE SIZE
For more info, please visit https://www.drugtimes.cn/english-content
-
科睿唯安交易并购报告 | 2020年第二季度行业纵览与解析
原文始发于微信公众号（科睿唯安生命科学与制药）：科睿唯安交易并购报告 | 2020年第二季度行业纵览与解析 ⬆️欢迎参加2020中国新药CMC高峰论坛！ 交易引领生物制药行业发展 …
